glp-1 drug exposure pharmaceutical companies 2025 SUSTAINABLE DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND glp-1 drug exposure pharmaceutical companies
Description
Furthermore, FAERS includes only cases where AEs occurred rather than complete adverse reaction reports
[PubMed ID: 19557413]
Retrieved 25 August 2025
Analysts say the move could intensify competition in a market already dominated by blockbuster GLP-1 drugs and reshape how obesity is treated in primary care
"The usual safety precautions have been bypassed, in one way or another, and this increases the medical risk of using such a product." Dumont noted there's a good reason prescription drugs are tightly regulated, from the FDA approval process to how they are manufactured and prescribed
